ERBB2 and neoplasm: Cofactors included age at BM, performance status, menstrual status, tumor size, lymph node involvement, ER, PR, HER2 expression, molecular subtype, number of bones involved, site of the involved bone, stage of BM, other organ metastases, time from BC diagnosis to BM, and the duration of ZA treatment (Table 6).